As announced in an earlier news release, the first purchase order from Laguna Blends is for $100,000 CDN. This purchase order is the first installment of a definitive agreement with Laguna Blends to produce $1,600,000 CDN of Pro369, in the first year of the Agreement, and $4,500,000 CDN of Pro369 in the second year of the Agreement. Naturally Splendid CEO Craig Goodwin reports, “It is anticipated that Laguna will place a second Purchase Order estimated to be $250,000 CDN by the second quarter of 2016. We are working closely with Laguna as they prepare for their launch and ramping up of sales.”
Pro369 has been custom formulated for Laguna Blends by Naturally Splendid. Naturally Splendid VP of Operations Bryan Carson states, “Naturally Splendid is prepared for production with packaging and ingredients ordered and production time slotted for the last week of January 2016. Naturally Splendid has custom formulated Pro369 in four flavours. The Minister of Health has granted Laguna a product license along with a Natural Product Number for all four of the Pro369 Flavours. We are proud that all four (4) custom formulated proteins were approved by Health Canada and are now focused on the move into the production phase with Laguna Blends. These are exciting times for Naturally Splendid as we begin to monetize the products we have developed.”
In order to obtain authorization to legally sell as a natural health product in Canada, a product license application must be submitted to Health Canada. To obtain a license to sell a natural health product, applicants must give detailed information about the product to Health Canada, including: medicinal ingredients, source material, dosages, potency, non-medicinal ingredients and recommended use(s).
Pro369 is a unique blend of hemp protein, HempOmega™ and other plant-based ingredients within the offering from Naturally Splendid’s 100% owned, BC Ingredients (bcingredients.com). The HempOmega™ infused protein formulations are water-soluble and can be directly mixed in water, juices, dairy, or dairy alternatives such as almond, coconut, soy or rice milk.”
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.
CFN Enterprises Inc. Launches Cannabis News Series to Broadcast on Bloomberg, Newsmax & Fox Business
CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)
CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.